Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-202/HB-201 Alternating Therapy with Pembrolizumab in HPV16+ OPSCC
NCT06513884Phase 3Withdrawn
- Sponsor
- HOOKIPA Pharma
- Start
- Dec 2024
- Primary completion
- Nov 2029
- Modality
- Oncolytic Viruses, Cancer Vaccines
01
Overview
Phase 3, randomised, double-blind trial of HB-202 and HB-201 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by HOOKIPA Pharma. Primary endpoints: Objective Response Rate up to 7.5 years and Overall Survival up to 7.5 years. Planned start Dec 2024; status: withdrawn.
02
Drugs
HB-202HB-201
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06513884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513884.